



Scientific Committee on Consumer Products

SCCP

**OPINION ON**  
**Diethylamino hydroxybenzoyl hexyl benzoate**

COLIPA n° S83



The SCCP adopted this opinion at its 15<sup>th</sup> plenary of 15 April 2008

### About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

### SCCP

Questions concerning the safety of consumer products (non-food products intended for the consumer).

In particular, the Committee addresses questions related to the safety and allergenic properties of cosmetic products and ingredients with respect to their impact on consumer health, toys, textiles, clothing, personal care products, domestic products such as detergents and consumer services such as tattooing.

### Scientific Committee members

Claire Chambers, Gisela Degen, Ruta Dubakiene, Bozena Jazwiec-Kanyion, Vassilios Kapoulas, Jean Krutmann, Carola Lidén, Jean-Paul Marty, Thomas Platzek, Suresh Chandra Rastogi, Jean Revuz, Vera Rogiers, Tore Sanner, Günter Speit, Jacqueline Van Engelen, Ian R. White

### Contact

European Commission  
Health & Consumer Protection DG  
Directorate C: Public Health and Risk Assessment  
Unit C7 - Risk Assessment  
Office: B232 B-1049 Brussels  
[Sanco-Sc6-Secretariat@ec.europa.eu](mailto:Sanco-Sc6-Secretariat@ec.europa.eu)

© European Commission 2008

(ISSN)

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

[http://ec.europa.eu/health/ph\\_risk/risk\\_en.htm](http://ec.europa.eu/health/ph_risk/risk_en.htm)

---

## ACKNOWLEDGMENTS

Dr. C. Chambers  
Prof. G. Degen  
Dr. B. Jazwiec-Kanyion  
Prof. V. Kapoulas  
Prof. J.-P. Marty  
Prof. T. Platzek  
Dr. S.C. Rastogi  
Prof. J. Revuz  
Prof. V. Rogiers  
Prof. T. Sanner (Chairman and rapporteur)  
Dr. J. van Engelen  
Dr. I.R. White

Keywords: SCCP, scientific opinion, uv-filter, S83, diethylamino hydroxybenzoyl hexyl benzoate, directive 76/768/ECC, CAS 302776-68-7, ELINCS 443-860-6

Opinion to be cited as: SCCP (Scientific Committee on Consumer Products), Opinion on diethylamino hydroxybenzoyl hexyl benzoate, 15 April 2008

---

**TABLE OF CONTENTS**

ACKNOWLEDGMENTS	.....	3
1. BACKGROUND	.....	5
2. TERMS OF REFERENCE	.....	5
3. OPINION	.....	6
4. CONCLUSION	.....	24
5. MINORITY OPINION	.....	24
6. REFERENCES	.....	24

## 1. BACKGROUND

Diethylamino hydroxybenzoyl hexyl Benzoate (CAS 302776-68-7) was introduced as an UV – filter in the Cosmetics Directive in annex VII entry 28 based on two SCCNP<sup>1</sup> scientific opinions (SCCNFP/0650/03) adopted during its 24th plenary meeting of 24-25 June 2003 and (SCCNFP/0756/03) adopted during its 25th plenary meeting of 20 October 2003.

Due to some discussions about the interpretation of the preamble to Annex VII the authorised UV-filters "*may be added to other cosmetic products within the limits and under the conditions laid down in this annex*", the SCCP was asked, whether the substance also could be considered safe for the consumers when used in cosmetic products other than sunscreen products in a concentration of up to 10%.

The SCCP re-evaluated the substance and adopted, during its 8th plenary meeting of 20 June 2006, the opinion (0996/06) with the conclusion that:

*"the information submitted does not conform to current standards and guidelines for the safety evaluation of cosmetic ingredients. Before any further consideration, the following information is required:*

- *an absorbance spectrum of the substance*
- *a mammalian gene mutation test.*

*The applicant should specify for what other purposes the substance should be used."*

The requested information is contained in the current submission.

## 2. TERMS OF REFERENCE

1. *Does the SCCP consider that the use of the Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester is safe for the consumer in a concentration up to 10 % when used in cosmetic products including sunscreen products?*
2. *Does the SCCP propose any further restrictions or conditions for its use in other cosmetic products?*

---

<sup>1</sup> The Scientific Committee on Cosmetic Products and Non-Food Products intended for Consumers, the predecessor of the current SCCP

### 3. OPINION

#### 3.1. Chemical and Physical Specifications

##### 3.1.1. Chemical identity

###### 3.1.1.1. Primary name and/or INCI name

Diethylamino Hydroxybenzoyl Hexyl Benzoate (INCI name)

###### 3.1.1.2. Chemical names

Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester  
2-(4-Diethylamino-2-hydroxybenzoyl)-benzoic acid hexylester


###### 3.1.1.3. Trade names and abbreviations

Trade name: Uvinul® A Plus  
COLIPA n°: S83

###### 3.1.1.4. CAS / EINECS/ELINCS number

CAS: 302776-68-7  
ELINCS: 443-860-6 (Uvinul A Plus)

###### 3.1.1.5. Structural formula



###### 3.1.1.6. Empirical formula

Formula:  $C_{24}H_{31}NO_4$

##### 3.1.2. Physical form

Nearly white fine-grained powder

##### 3.1.3. Molecular weight

Molecular weight: 397.52

##### 3.1.4. Purity, composition and substance codes

Purity: Min: 98%

## Opinion on diethylamino hydroxybenzoyl hexyl benzoate

## 3.1.5. Impurities / accompanying contaminants

Impurities	
Methanol	0.017 g/100 g
1-hexanol	< 0.01g/100 g
Phthalic acid + phthalic anhydride	< 0.01g/100 g

## 3.1.6. Solubility

In water: < 0.01 mg/l at 20 °C and pH about 6-7

3.1.7. Partition coefficient (Log P<sub>ow</sub>)

Log P<sub>ow</sub>: 6.2

## 3.1.8. Additional physical and chemical specifications


Melting point:	54 °C; 314 °C (decomposition temperature)
Boiling point:	no boiling at normal pressure
Density:	1.156 (D <sub>4</sub> <sup>20</sup> )
Rel. vapour density:	/
Vapour Pressure:	2.9 10 <sup>-8</sup> hPa (p <sub>20°C</sub> ); 7.9 10 <sup>-7</sup> hPa (p <sub>50°C</sub> )

## 3.1.9. Stability

The substance appears to be stable for 3 months at 25°C, 60% relative humidity and 40 °C, 75% relative humidity

## 3.1.10. Absorbance spectrum

Solvent	β (g/l)	λ <sub>max</sub> (nm)	ε (l / mol cm)
methanol	0.0142, 0.0284, 0.0142	356, 266, 210	38407, 5749, 28306
0.1 M meth. HCl	0.007236, 0.01 1712	358, 210	33961, 28469
0.1 M meth. NaOH	0.006012 and 0.007604	357, 220	32949, 20355



### 3.2. Function and uses

Up to 10% in sunscreen products, alone or in combination with other UV absorbers.

Requested use: up to 10% when used in other cosmetic products than sunscreen products (e.g. hand cream, face cream, body lotion).

Uvinul® A Plus is an oil soluble UVA filter that can be readily incorporated in the oil phase of emulsions.



### 3.3. Toxicological Evaluation

#### 3.3.1. Acute toxicity

##### 3.3.1.1. Acute oral toxicity

#### **Taken from opinion SCCP 0996/06**

Guideline: OECD 423 (1996)  
 Species/strain: Wistar rats  
 Group size: 3 males + 3 females (9 – 17 weeks old)  
 Test substance: Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester  
 Batch: R 323/681  
 Purity: 99.35%  
 Dose level: 2000 mg/kg bw in 0.5% Tylose CB 30.000 in Aqua bi-distillated  
 Route: Oral, gavage, administration volume 10 ml  
 Observation: 14 days  
 GLP: In compliance

Under the conditions of this study the median lethal dose of the test substance after oral dosing was found to be greater than 2000 mg/kg bw for the male and female rats.

Ref.: 1

##### 3.3.1.2. Acute dermal toxicity

No data submitted

##### 3.3.1.3. Acute inhalation toxicity

No data submitted

#### 3.3.2. Irritation and corrosivity

##### 3.3.2.1. Skin irritation

#### **Taken from opinion SCCP 0996/06**

#### **Acute**

Guideline: OECD 404 (1992)  
 Species/strain: White New Zealand Rabbits  
 Group size: 3 young adult  
 Test substance: Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester  
 Batch: R 323/681  
 Purity: 99.35%  
 Dose level: A single topical application of 0.5 g to the intact skin for 4 hours under semi-occlusive dressing  
 Route: Topical  
 Exposure period: 4 hours  
 Observation: 72 hours  
 GLP: in compliance

Slight erythema was observed in 2 animals on the day of application. No oedema was observed. The third animal did not show any skin reactions. The cutaneous reactions were reversible

in the animals within 48 hours after removal of the patch at latest. The average score (24 to 72 hours) for irritation was calculated to be 0.1 for erythema and 0.0 for oedema.

Considering the observed cutaneous reactions as well as the average score for irritation, the test substance was not irritant to the skin under the test conditions.

Ref.: 2

### **Taken from opinion SCCP 0996/06**

#### **Repeated exposure**

Guideline: /  
 Species/strain: Guinea pigs / Had Poc: DH (SPF)  
 Group size: 3 males and 3 females, 8 weeks old at start of experiment  
 Test substance: Uvinul A Plus  
 Batch: Labor Jr Nr. 31656/25-5  
 Purity: 98.8%  
 Dose level: Daily applications with 50 µl of a 10% or 20% solution in propylene glycol for 14 days without use of dressing.  
 Route: Topical  
 Exposure period: 14 days  
 Observation: 24 hours after application  
 GLP: in compliance

There are no guidelines for the conduct of a 14-day skin irritation study available. The study was performed following the "Guidance for cosmetic safety evaluation" issued by the Japan Cosmetic Industry Association 2001, the EMEA/CPMP guidance document (The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP): Note for guidance on non-clinical local tolerance testing of medicinal product. CPMP/SWP/2145/00: March 2001) and the method of Marzulli and Maibach (Marzulli F.N., Maibach H.I., The rabbit as a model for evaluating skin irritants: a comparison of results obtained on animals and man using repeated skin exposures. Food Cosmet.Tox. 13: 533-540, 1975).

The skin irritation of Uvinul A Plus in guinea pigs was examined by 14 open applications over a study period of 2 weeks. Two groups of 3 male and 3 female animals, each, were used and the test substance together with the negative control was tested on the right respectively left flank of the animals of a test group. Thus one test substance concentration and vehicle control were tested in each animal.

Amounts of 50 µl of test substance preparations in propylene glycol respectively the vehicle were applied to the intact skin in the flank region without use of dressing. Fourteen applications were performed daily over a study period of 2 weeks. The readings of skin reactions were performed 24 hours after each application.

Under the test conditions used in this study, the test substance concentrations did not cause skin reactions different from or discernibly more severe than those observed at the skin sites treated with the vehicle propylene glycol, alone. Furthermore no concentration response relation was present.

Ref.: 15

#### **3.3.2.2. Mucous membrane irritation**

### **Taken from opinion SCCP 0996/06**

Guideline: OECD n° 405 (1987)

## Opinion on diethylamino hydroxybenzoyl hexyl benzoate

Species/strain:	White New Zealand Rabbits
Group size:	3 young adult
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch no:	R 323/681
Purity:	99.35%
Dose level:	One single ocular application of 0.1 ml bulk volume (about 40 mg). 24 hours after application, the eye was rinsed with tap water
Route:	Ocular application
Exposure period:	24 hours
Observation:	72 hours
GLP:	in compliance

Slight to moderate conjunctival redness was observed in all animals on the day of application. Additionally, slight discharge was seen in 1 animal. The ocular reactions were reversible in all animals within 48 hours after application at latest. The average score (24 to 72 hours) for irritation was calculated to be 0.0 for corneal opacity, iris and chemosis and 0.3 for conjunctival redness.

The test substance caused transient irritation of the eye under the test conditions.

Ref.: 3

3.3.3. Skin sensitisation
---------------------------

**Taken from opinion SCCP 0996/06**

**Maximization Test in Guinea Pigs**

Guideline:	OECD 406 (1992)
Species/strain:	Guinea pigs
Group size:	10 animals in test group and 5 + 5 in control groups, young adult females (Bodyweight 327 – 375 g at beginning of study)
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R 323/681
Purity:	99.35%
Dose level:	Intradermal induction: Test substance 5% in olive oil or 5% in Freund's adjuvant, 10.9% aqueous NaCl-solution (1:1)
Epicutaneous induction:	Test substance 25 % in olive oil
Challenge:	Test substance 25 % in olive oil
Route:	Intradermal and epicutaneously occlusive
Exposure period:	24 hours
Observation:	72 hours
GLP:	In compliance

For intradermal induction, the test animals received 6 injections (2 injections of a 0.1 ml Freund's adjuvant/aqua dest 1:1, 2 injections of 0.1 ml of a 5% test substance formulation, 2 injections of a 0.1 ml 5% test substance formulation in Freund's adjuvant/aqua dest 1:1). The intradermal induction with 5% test substance preparations caused moderate and confluent erythema and swelling or intense erythema and swelling in test group animals at 24 h after application.

Percutaneous induction was carried out 1 week after intradermal induction. The test substance (25% in olive oil) and the vehicle were applied for 48 h to the animals under occlusive conditions. Incrustation, erythema and oedema were observed in test and control animals at 48 h after beginning of application. After the epicutaneous induction, incrustation, partially open (caused by the intradermal induction) could be observed in addition to moderate and confluent erythema and swelling in all test groups animals.

A challenge with a 25% test substance preparation in olive oil was performed 14 days after the epicutaneous induction. No skin reactions could be observed neither in control group 1 nor in

## Opinion on diethylamino hydroxybenzoyl hexyl benzoate

the test group, 24 and 48 hours after removal of the patches. Olive oil, which was applied as a vehicle control to all animals, did not cause any skin reactions. Since no borderline results were observed, a 2<sup>nd</sup> challenge was not performed.

A positive control was not included in the study. Separate studies with a positive control (alpha-hexylcinnamaldehyde tech. 85%) are performed twice a year.

It was concluded that the test substance does not have a sensitising effect on the skin of the guinea pig in the Maximization Test under the test conditions.

Ref.: 10

Comment

Several questions may be raised concerning the study. The study cannot be evaluated.

3.3.4. Dermal / percutaneous absorption
---

**Taken from opinion SCCP 0996/06**

**Study 1**

Guideline:	OECD draft 428 (2000)
Test substance:	Cosmetic formulation (about 10% benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester) (o/w emulsion, no composition stated).
Batch:	R323/681
Purity:	99.35%
Dose applied:	2 mg/cm <sup>2</sup> and 10 mg/cm <sup>2</sup> ; active substance 200 µg/cm <sup>2</sup> and 1 000 µg/cm <sup>2</sup>
Skin preparation:	Full-thickness pig skin (epidermis and dermis). The method of skin preparation and the storage conditions of skin preparations were vaguely described
Skin temperature:	32 ± 1 °C
Exposure period:	24 h
Donor chamber:	Occlusion (covered with parafilm)
Receptor fluid:	1:1 Ethanol/water. Solubility in receptor fluid is 1.28 mg/ml.
Control:	The vehicle served as a control. No reference substance used.
Skin integrity:	Membrane integrity was visually checked prior to the test, not during the test.
Reproducibility:	Overall recovery results (respectively 6 and 7 membranes /group): Group 2 (2 mg/cm <sup>2</sup> ) recoveries: Membrane: 5.99 to 21.42%, leading to 10.54 ± 5.59 % Receptor compt.: 0.13 to 1.54%, leading to 0.86 ± 0.46% Group 3 (10 mg/cm <sup>2</sup> ) recoveries: Membrane: 2.62 to 12.54%, leading to 6.22 ± 4.23% Receptor compt.: 0.18 to 2.82%, leading to 1.05 ± 1.20%
Recovery:	Mean total recovery of 83 and 102 %
GLP:	In compliance

As it could be demonstrated by repeated extractions, most of test substance was found in the donor compartment, but particularly in the membrane washings, followed by the epidermal membrane. Only 0.9% (group 2) respectively 1.0% (group 3) of the applied dose was found in the receptor compartment after the exposure period of 24 h. Therefore, the applicant assumed that most of the amount found in the epidermal membrane is located in the upper layers of the stratum corneum which will most probably not be absorbed.

Remarks

- \* 7 out of the 20 membranes had to be excluded from the study due to low recovery rates (below 80%) and/or due to leakage of receptor fluid on the upper side of the membrane.

- \* Tape stripping has not been performed in order to check the stratum corneum theory of the applicant. Viewing the fact that application of higher amounts of test substance induce higher amounts penetrated, it is not self-evident that this theory can be supported and that the amount in the SC can be ignored.
- \* The receptor fluid does not meet the demand and thus was regarded as inappropriate.  
Ref.: 13

**Comment**

The percutaneous absorption study cannot be considered as valid due to the shortcomings mentioned above.

**Taken from opinion SCCP 0996/06  
Study 2**

Guideline:	OECD draft 428 (2000)
Test substance:	Cosmetic formulation (10% benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester) (o/w emulsion, no composition stated). Solubility in receptor fluid is 1.24 mg/ml.
Batch:	30956/121D2 +/122D
Purity:	97.9%
Dose applied:	2 mg/cm <sup>2</sup> for 24 hours (finite dose scenario); active substance 200 µg/cm <sup>2</sup>
Skin preparation:	Full-thickness pig skin (dermatomed skin) For the a.i.: 500 µm thickness For caffeine: 1000 µm thickness.
Skin temperature:	32°C
Exposure period:	24 h
Donor chamber:	No specification: occluded / unoccluded
Receptor fluid:	Krebs-Ringer bicarbonate buffer supplemented with 1% bovine serum albumin. Solubility of a.i. = 12.353 µg/ml.
Control:	No control was used.
Skin integrity:	Caffeine (10 mg/ml) in buffer was used as a marker compound, at 2 ml on the skin preparation (infinite dose scenario).
Recovery:	Mean 92.7% ± 4.8%
GLP:	In compliance

Dermatomized porcine skin biopsies (ca. 500 µm) were mounted into Franz diffusion cells and incubated with the test formulation (2 mg/cm<sup>2</sup> skin; 0.2 mg/cm<sup>2</sup> benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester) for 24 h. The experiment was performed in triplicate using 3 different pigs. At the end of the permeation study, the skin biopsies were separated into stratum corneum layers and deeper skin by tape stripping and quantified for benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester. Samples of the receptor fluid (1% bovine serum albumin in Krebs Ringer bicarbonate buffer) were analysed in suitable intervals and at the end of the incubation period (sensitivity of detection not mentioned).

The mean recovery was 93%. No permeation of benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester through the skin biopsies into the receptor medium could be observed. A minor amount (0.77%) was absorbed in the upper layers of stratum corneum clearly graded from amounts within the deeper skin layers (0.100 ± 0.115 µg/cm<sup>2</sup>; 0.042 ± 0.050%; max value 0.310 µg/cm<sup>2</sup>; 0.149%).

Ref.: 14

**Comment**

The percutaneous absorption study no. 2 can be considered as valid. The percutaneous absorption was 0.10 ± 0.12 µg/cm<sup>2</sup> or 0.04 ± 0.05% (Maximum value 0.31 µg/cm<sup>2</sup> or 0.15%).

## 3.3.5. Repeated dose toxicity

## 3.3.5.1. Repeated dose (28 days) oral / dermal / inhalation toxicity

No data submitted

## 3.3.5.2. Sub-chronic (90 days) oral / dermal / inhalation toxicity

**Taken from opinion SCCP 0996/06****Oral**

Guideline: OECD 408 (1998)  
 Species/strain: Wistar rats CrI: W1 (GLX/BRL/HAN) IGS BR  
 Group size: 10 animals per sex and dose (42 days old at start of study)  
 Test substance: Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester  
 Batch: R 323/681  
 Purity: 99.35%  
 Dose levels: 0, 600 ppm (males: approx 51.7 mg/kg bw/d; females: approx 59.3 mg/kg/d), 3,000 ppm (males: approx 250.2 mg/kg bw/d; females: approx 288.0 mg/kg bw/d), 15,000 ppm (males: approx. 1249 mg/kg bw/d; females: approx 1452 mg/kg bw/d)  
 Route: Oral, in diet  
 Exposure period: 90 days  
 GLP: In compliance

Clinical examinations revealed no substance-related effects. Clinical pathology also showed no substance-related effects.

The mean relative liver weights in male (+7%) and female rats (+10%) in high dose group were statistically significantly increased. However, the lack of any morphological changes supports the assumption that this is not an adverse effect. Additionally, the absolute weights were not significantly decreased in either males (-3.6%) and females (-2.5%) in the high dose group. The mean relative weights of testes (+ 9%, high dose group) and heart (female, low dose group +15%) were significantly increased. Whereas the mean relative weight of the spleen (mid dose group in females) was significantly decreased (-31%), the applicant does not regard this as treatment related.

All gross lesions and microscopic findings recorded were either single observations, or they occurred in control animals only, or they were recorded at low or comparable incidence and graded severity in control and high dose males and/or females. These changes are all considered to be unrelated to treatments by the applicant. Comprehensive examinations of reproductive organs as well as sperm analysis did not give any indication for an impairment of fertility.

**Conclusion**

The study authors considered that the NOAEL was equal to the highest dose used. That is 15,000 ppm (1248.8 mg/kg bw/day in males; 1452.1 mg/kg bw/day in females).

Ref.: 11

**Comment**

Based on the increase in relative liver weight (+7% in male rats), the NOEL was set at 3000 ppm (250 mg/kg bw/day).

## 3.3.5.3. Chronic (&gt; 12 months) toxicity

No data submitted

## 3.3.6. Mutagenicity / Genotoxicity

3.3.6.1. Mutagenicity / Genotoxicity *in vitro***Taken from opinion SCCP 0996/06****Bacterial Reverse Mutation Test**

Guideline:	OECD 471
Species/strains:	<i>Salmonella typhimurium</i> TA98, TA100, TA1535, TA1537 and <i>Escherichia coli</i> WP2 uvrA
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R323/681
Purity:	99.35%
Replicates:	3 plates per test
Concentrations:	Standard plate test: 20 µg - 5,000 µg/plate (in DMSO) Preincubation test: 4 µg - 2,500 µg/plate (in DMSO)
Test conditions:	Standard plate test and preincubation test both with and without metabolic activation (Aroclor-induced rat liver S9-mix)
Solubility:	Precipitation of the test substance was found from about 500 µg/plate onward
GLP:	In compliance

The test substance has been investigated for the induction of gene mutation in *Salmonella typhimurium* and *Escherichia coli*. Liver S9 fraction from Sprague Dawley induced with Aroclor 1254 was used as the exogenous metabolic activation system. Negative and positive controls were in accordance with the OECD guideline.

A slight decrease in the number of revertants was observed in the standard plate test depending on the strain and test conditions from about 500 µg – 2,500 µg/plate onward. In the preincubation assay a weak bacteriotoxic (slight decrease in the number of revertants and/or slight reduction in the titer) was observed depending on the strain and test conditions from about 100 µg – 500 µg/plate onward. Test substance precipitation was found from 500 µg/plate onward.

An increase in the number of his<sup>+</sup> or trp<sup>+</sup> revertants was not observed in the standard plate test or in the preincubation test either without or with S9-mix as metabolising system.

Ref.: 4

**Comment**

The test substance is not mutagenic in the *Salmonella typhimurium/Escherichia coli* reverse mutation assay under the experimental conditions used.

***In vitro* Mammalian Cell Gene Mutation Test (*tk*<sup>+/-</sup> locus)**

Guideline:	OECD guideline 476
Species/strain:	Mouse lymphoma cell line L5178Y ( <i>tk</i> -locus)
Replicates:	duplicates in two independent experiments
Test substance:	Uvinul A Plus
Solvent:	DMSO
Batch:	PBG+Charge: 00000677LO
Purity:	98.7% (HPLC)

## Opinion on diethylamino hydroxybenzoyl hexyl benzoate

---

Concentrations:	Experiment 1: without metabolic activation (4 h treatment): <b>1.9</b> , 3.9, 7.8, 15.6, 31.3, 62.5 µg/ml with metabolic activation (4 h treatment): <b>7.8</b> , 15.6, 31.3, 62.5, 125, 250 µg/ml
	Experiment 2: without metabolic activation (24 h treatment): <b>0.47</b> , <b>0.94</b> , 1.9, 3.8, 7.5, 10.0, 15.0 µg/ml with metabolic activation (4 h treatment): 6.3, 12.5, 25.0, 50.0, 100, <b>200</b> µg/ml
Treatment:	Experiment 1: 4 h treatment with and without S9-mix, 48 expression period, selection growth 10 – 15 days
	Experiment 2: 3 h treatment with S9-mix, 48 expression period, selection growth 10 – 15 days 24 h treatment without S9-mix, 48 expression period, selection growth 10 – 15 days
GLP:	In compliance

The test substance was examined for its genotoxic potential in the L5178Y TK<sup>+/−</sup> mouse lymphoma test in the absence and presence of metabolic activation (Phenobarbital/β-Naphthoflavone induced rat liver S9-mix). A range-finding test (pre-test on toxicity, measuring relative suspension growth) and two independent mutagenicity experiments were carried out. The concentrations for Experiment 1 and 2 were selected based on the results of the range-finding experiment. Culture medium and DMSO were used as negative and solvent controls, while methyl methane sulfonate (MMS; 19.5 µg/ml, Experiment 1, 13.0 µg/ml, Experiment 2) and cyclophosphamide (CPA; 4.5 µg/ml, Experiment 1, 3.0 µg/ml, Experiment 2) were used as positive controls in experiments without and with metabolic activation system, respectively. Two parallel cultures were investigated for each concentration and test group. Mutant frequency and cell survival (measured as cloning efficiency) were determined in parallel.

### Results

Turbidity of test item was noted at 31.3 and 62.5 µg/ml in the absence and at 125 and 250 µg/ml the presence of metabolic activation. Precipitation was observed at 2000 µg/ml. Relevant toxic effects were already observed at the lowest concentration of 31.3 µg/ml and above in the absence (4 h treatment) and at 62.5 µg/ml in the presence of metabolic activation (4 h treatment). Following continuous treatment (24 hours) a reduced relative suspension growth was determined at 7.5 µg/ml and above in the second pre-test. The concentrations of both main experiments were chosen with respect to the solubility and toxicity data generated in the pre-experiment. To overcome problems with possible deviations in toxicity both main experiments were started with more than four concentrations. In experiment 1, following the expression phase of 48 hours the cultures at 1.9 µg/ml without S9-mix (printed in bold letters) and 7.8 µg/ml with S9-mix were not continued since a minimum of only four analysable concentrations is required by the guidelines. In experiment 2 the cultures at 0.5 and 0.9 µg/ml without S9-mix were not continued for the same reason. The cultures at the maximum concentration of 200 µg/ml in experiment 2 with S9-mix were not continued due to exceedingly strong toxic effects.

A test item is classified as mutagenic if the induced mutation frequency reproducibly exceeds a threshold of 126 colonies per 10<sup>6</sup> cells above the corresponding solvent control or negative control, respectively. No substantial and reproducible dose dependent increase of the mutation frequency was observed up to the maximum concentration with and without metabolic activation. The threshold of 126 plus each solvent control count was not reached or exceeded at any test point. A linear regression analysis (least squares) was performed to assess a possible dose dependent increase of mutant frequencies. A significant dose dependent trend of the mutation frequency indicated by a probability value of <0.05 was determined in almost all experimental groups with exception of the second culture without metabolic activation in the first experiment and the second culture with metabolic activation in the second experiment. However, all absolute values of the mutation frequency in both



experiments remained well within the historical control range indicating that the observed trends are based on minor increases at cytotoxic concentrations. Such minor increases not exceeding the historical control range are common to this assay system and judged as biologically irrelevant.

#### Conclusion

The study authors concluded that under the experimental conditions reported the test item did not induce mutations in the mouse lymphoma thymidine kinase locus assay using the cell line L5178Y in the absence and presence of metabolic activation.

Ref.: I

#### Comment

Uvinul A Plus did not induce mutations in the mouse lymphoma thymidine kinase locus assay using the cell line L5178Y in the absence and presence of metabolic activation under the experimental conditions used.

### **Taken from opinion SCCP 0996/06**

#### **Chromosome Aberration Assay in V79 Cells**

Guideline:	OECD 473
Species/strains:	V79 cells derived from Chinese Hamster
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R323/681
Purity:	99.35%
Cell system:	V79 cell line in MEM medium with glutamine supplemented with 10% foetal calf serum (not during exposure to the test substance), 1% penicillin/streptomycin, 1% amphotericine
Concentrations:	vehicle: DMSO
	1 <sup>st</sup> experiment
	4 h exposure, 18 h harvest time, - S-9 mix: 0; 5.0; 10.0; 20.0 µg/ml
	4 h exposure, 18 h harvest time, + S-9 mix: 0; 10.0; 20.0; 40.0 µg/ml
	2 <sup>nd</sup> experiment
	18 h exposure, 18 h harvest time, - S-9 mix: 0; 2.5; 5.0; 10.0 µg/ml
	18 h exposure, 28 h harvest time, + S-9 mix: 0; 10.0 µg/ml
	4 h exposure, 28 h harvest time, + S-9 mix: 0; 10.0; 20.0; 40.0 µg/ml

The test substance has been investigated for the induction of chromosome aberrations in V79 cells. Liver S9 fraction from Sprague Dawley induced with Aroclor 1254 was used as the exogenous metabolic activation system. Negative and positive controls were in accordance with the OECD guideline.

About 2-3 hours prior to harvesting the cells, colcemid was added to arrest cells in a metaphase-like stage of mitosis (c-metaphases). After preparation of the chromosomes and staining with Giemsa, 100 metaphases for each culture in the case of the test substance and vehicle controls, or 50 cells for each culture in the case of the concurrent positive controls, were analyzed for chromosomal aberrations.

The test substance did not cause any increase in the number of structurally aberrant metaphases incl. and excl. gaps at both sampling times either without S-9 mix or after adding a metabolizing system in two experiments performed independently of each other. No increase in the frequency of cells containing numerical aberrations was demonstrated either.

Ref.: 5

#### Comment

The test substance is considered not to be a chromosome-damaging (clastogenic) agent under *in vitro* conditions in V79 cells.

3.3.6.2 Mutagenicity/Genotoxicity *in vivo*

No data submitted

## 3.3.7. Carcinogenicity

No data submitted

## 3.3.8. Reproductive toxicity

## 3.3.8.1. Two generation reproduction toxicity

No data submitted

## 3.3.8.2. Teratogenicity

***Taken from opinion SCCP 0996/06*****Prenatal Developmental Toxicity Study in Wistar Rats - Oral Administration (Gavage)**

Guideline:	OECD draft 414 (2000)
Species/strain:	Sexually mature, virgin Wistar rats (CRL:WI (GLX/BRL/HAN)IGS BR)
Group size:	25 mated rats
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester suspended in olive oil
Batch:	R 323/681
Purity:	99.35%
Dose level:	0, 40, 200, 1000 mg/kg bw/d
Route:	Oral (gavage, 5 ml/kg bw)
Exposure period:	Day 6 – 19 p.c.
GLP:	in compliance

The test substance was administered as an oily suspension to 25 mated female Wistar rats/group by stomach tube at doses of 40, 200, and 1,000 mg/kg bw on day 6 through day 19 post coitum. Maternal toxicity, by transient salivation, reduced food consumption on day 6 - 13 p.c. and slight alterations in absolute and corrected body weight gain were noted at 1,000 mg/kg bw/day. No signs of substance-induced maternal toxicity occurred at dose levels of 40 or 200 mg/kg bw/d.

There were no substance-induced, dose related influences on the gestational parameters and no signs of prenatal developmental toxicity, especially no substance induced indications of teratogenicity, up to and including the highest dose level (1000 mg/kg bw/d).

Ref.: 12

## Comment

The no observed adverse effect level (NOAEL) for maternal toxicity is 200 mg/kg bw/day, while it is 1000 mg/kg bw/day (highest applied dose) for prenatal developmental toxicity.

A comparison between the above-mentioned results and those derived from the 90-day study (NOAEL / NOEL) may be influenced by administration (diet versus gavage).

## 3.3.9. Toxicokinetics

No data submitted

## 3.3.10. Photo-induced toxicity

## 3.3.10.1. Phototoxicity / photoirritation and photosensitisation

**Taken from opinion SCCP 0996/06****Cytotoxicity Assay *in vitro*: Neutral Red (NR) Assay at simultaneous Irradiation with Artificial Sunlight**

Guideline:	OECD draft 'In vitro 3T3 NRU phototoxicity test, (2000) EU n° B.41 (2000)
Species/strain:	Balb/c 3T3 cells clone 31
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R323/681
Purity:	99.35%
Concentrations:	0, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50, and 100 µg/ml. The test substance was dissolved in DMSO
Artificial sunlight:	Dr. Honle Sol 500 solar simulator. Wavelength of the solar simulator with the filter was > 320 nm. Dose: 1.7 mW/cm <sup>2</sup> (the UV intensity underneath the lid) for 50 min at room temperature (= 5 J/cm <sup>2</sup> ).
GLP:	In compliance

After 1 h pre-incubation with 8 concentrations of the test substance or the positive control (chlorpromazine; 6.25 – 200 µg/ml without irradiation and 0.125 – 40 µg/ml with irradiation), the cells were irradiated with artificial sunlight. Parallel cultures were kept in the dark. The cytotoxic response curves of the test groups were compared. The EC<sub>50</sub>-values were determined and compared to calculate a photo-irritancy factor (PIF) to measure a possible phototoxicity.

No toxicity was observed in the absence of irradiation and only a slight toxicity was observed in the presence of irradiation with artificial sunlight. Therefore, only a ">PIF" value could be calculated. The EC<sub>50</sub> value in the presence of irradiation (95 µg/ml) was determined graphically, the maximum tested concentration C<sub>max</sub> in the absence of irradiation is 100 µg/ml, resulting in a >PIF of 1.05. This, however, is not biologically relevant in this case.

Ref.: 9

**Comment**

In the study described and under the experimental conditions reported no phototoxic potential was observed after treatment of Balb/c3T3 cells in the absence and in the presence of artificial sunlight.

**Taken from opinion SCCP 0996/06****Phototoxic and Photoallergenic Potential by Cutaneous Route in Guinea Pigs**

Guideline:	/
Species/strain:	Dunkin-Hartley guinea pigs, male
Group size:	5 or 10 animals per group
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R323/681
Purity:	99.35%
UV irradiation:	Toxicotronic 312/365 nm (Vilbert/Lourmat). The lamp consists of two groups of three fluorescent tubes producing either UVA (365 nm) or UVB (312nm). The irradiation was performed in two stages, first irradiation with UVB and then irradiation with UVA at an infra-erythematogenic irradiation dose (score of erythema ≤ 0.5). The irradiation doses were 9 joules/cm <sup>2</sup> for UVA and 0.1 joule/cm <sup>2</sup> for UVB.

**Opinion on diethylamino hydroxybenzoyl hexyl benzoate**


---

Dose levels:	0.2 ml of the test substance at the concentration of 10 or 20% (w/w) in olive oil
Groups:	Group 1(5 animals): irradiated control group Group 2 (5 animals): group treated with the test substance Group 3 (10 animals): group treated with the test substance and irradiated Group 4 (5 animals): vehicle control group
Route:	Topical
Observation period:	1, 4, and 24 hours after the single application and/or irradiation.
GLP:	In compliance

The design of the study was based on the method published by Unkovic et al., Sci. Tech. Ani. Lab., 8, no 3: 149-160 (1983). The experiments were performed in the period 13/12/2000 to 12/1/2001.

The phototoxic potential of the test substance was evaluated 1 hour, 4 and 24 hours after the first treatment and/or irradiation performed on day 1 in animals of all groups. The photoallergenic potential of the test substance was assessed in animals of all groups after several treatments and/or irradiation during an induction period of 8 days on the anterior scapular area (6 applications - days 1 to 8), followed by a rest period of 20 days, then a challenge application and/or irradiation to the posterior area of the right (UVA) and left (UVB) flanks of the animals. At each treatment, a dose-volume of 0.2 ml of the test substance at the concentration of 10 or 20% (w/w) in olive oil was applied by cutaneous route. The irradiation dose of UVA and UVB was infra-erythemal. The cutaneous reactions were evaluated at the treatment site.

At the end of the study, animals were killed without examination of internal organs. Skin samples were taken from the challenge application sites of the animals showing skin reactions at the last observation. No histological examination was performed.

No clinical signs and no deaths were noted during the study. The body weight gain of the treated animals was similar to that of the control animals.

Phototoxic potential

The cutaneous reactions observed on days 1 and 2 in almost all animals of groups 1, 2, 3 and 4 remained within the range of a local reaction at an infra-erythemal irradiation dose (questionable or weak erythema) and were of similar incidence in control and treated groups. No cutaneous reactions which could be attributed to a photoirritant effect of the test substance were observed.

Photoallergenic potential

The cutaneous reactions observed on day 29 in almost all animals of groups 1, 2, 3 and 4 remained within the range of a local reaction at an infra-erythemal irradiation dose (questionable or weak erythema) and were of similar incidence in control and treated groups. No cutaneous reactions which could be attributed to a photoallergenic effect of the test substance were observed.

Ref.: 8

## Comment

Under the experimental conditions, two very specific wavelengths of UV radiation were used without information of the absorption spectra of the substance. Broadband UVA and UVB irradiation would more appropriately mimicked the intended use of this cosmetic UV-filter.

## 3.3.10.2. Phototoxicity / photomutagenicity / photoclastogenicity

**Taken from opinion SCCP 0996/06****Photomutagenicity in a *Salmonella typhimurium* and *Escherichia coli* Reverse Mutation Assay**

Guideline:	OECD 471 (1997)
Species/strains:	<i>Salmonella typhimurium</i> TA98, TA100, TA102, TA 1537 and <i>Escherichia coli</i> WP2
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R323/681
Purity:	99.35%
Replicates:	3 plates per test
Concentrations:	33 – 5000 µg/plate (in DMSO)
UV irradiation:	Source of light: Xenon-lamp (Suntest CPS, ATLAS) with a UV glass filter cutting off wave lengths below 290 nm. UV dose was chosen that increased the number of revertant colonies to approximately twice the number of spontaneous revertants without irradiation. (TA1537: 50 mJ/cm <sup>2</sup> UVA, 2.5 mJ/cm <sup>2</sup> UVB; TA98: 20 mJ/cm <sup>2</sup> UVA, 1.0 mJ/cm <sup>2</sup> UVB; TA100: 4 mJ/cm <sup>2</sup> UVA, 0.2 mJ/cm <sup>2</sup> UVB; TA102: 100 mJ/cm <sup>2</sup> UVA, 5.0 mJ/cm <sup>2</sup> UVB; and WP2: 9 mJ/cm <sup>2</sup> UVA, 0.28 mJ/cm <sup>2</sup> UVB)
GLP:	In compliance

This study was performed to investigate the potential of benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester to induce gene mutations under irradiation with artificial sunlight according to the plate incorporation test (experiment I) and the preincubation test (experiment II) using the *Salmonella typhimurium* strains TA1537, TA98, TA100, TA102, and the *Escherichia coli* strain WP2. The assay was performed in two independent experiments. Each concentration and the controls were tested in triplicate.

No substantial increase in revertant colony numbers of any of the five tester strains was observed following treatment with benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester at any dose level. There was also no tendency of higher mutation rates with increasing concentrations in the range below the generally acknowledged border of biological relevance. In experiment II (pre-incubation), the numbers of revertants of the irradiated bacteria are not always twice as high as compared to the non irradiated control. In contrast to the plate incorporation assay used in the first experiment, the bacteria are not irradiated at or close to the surface during preincubation in aqueous solution. In this design UV light may be partially absorbed by the solution prior to reaching the bacteria reducing the direct DNA damage. However since the colony count of the positive control clearly exceeded the threshold of twice the colony count of the corresponding solvent control the data are judged as valid. Appropriate reference mutagens were used as positive controls. They showed a distinct increase of induced revertant colonies. An irradiation specific positive control (8-methoxypsoralene) was only used with strains TA 102 and WP2. The performance of the other strains was ensured with conventional positive controls in the absence of irradiation.

In conclusion, it can be stated that during the described photomutagenicity test and under the experimental conditions reported, the test substance did not induce gene mutations by base pair changes or frameshifts in the genome of the strains used.

Ref.: 7

**Comment**

The test substance is considered to be non-mutagenic in this *Salmonella typhimurium* and *Escherichia coli* photomutagenicity assay.

**Taken from opinion SCCP 0996/06****Chromosome Aberration Test *in vitro*: Photo-mutagenicity in Chinese Hamster V79 Cells**

Guideline:	OECD n° 473 (1997)
Species/strains:	V79 cells derived from Chinese Hamster
Test substance:	Benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester
Batch:	R323/681
Purity:	99.35%
Concentrations:	2.5; 5.0; 10.0; 20.0; 40.0 and 80.0 µg/ml in DMSO
Cell system:	V79 cell line in MEM medium with glutamine supplemented with 10% foetal calf serum (not during exposure to the test substance), 1 % penicillin/streptomycin, 1% amphotericine
Light source:	Xenon-lamp (Suntest CPS, ATLAS) with an additional special filter glass, emitting visible and UVA/UVB light >290 nm
UV doses:	225/11.25 mJ/cm <sup>2</sup> UVA/UVB (exp. I and II) or 375/18.75 mJ/cm <sup>2</sup> UVA/UVB (exp. II)
Positive controls:	with irradiation: 8-Methoxypsoralene without irradiation: Ethylmethane sulfonate

The cultures were pre-incubated with the test substance for 30 min. After exposure to UV light and further 3 hours the cultures were washed twice. Corresponding cultures with the test substance were kept in the dark for 3 h exposure period. 18 hrs (exp. I) or 28 hrs (exp. II) after start of treatment, the cultures were prepared for cytogenetic evaluation. In the cytogenetic experiments for each experimental group two parallel cultures were set up. 100 metaphase per culture were scored for structural chromosome aberrations.

No biologically relevant increase in the number of cells carrying structural chromosomal aberrations was observed, neither in the absence nor in the presence of artificial sunlight. No increase in the frequencies of polyploid metaphases was found after treatment with the test substance as compared to the frequencies of the controls. Appropriate mutagens as positive controls induced statistically significant increases ( $p < 0.05$ ) in cells with structural chromosome aberrations.

Ref.: 6

**Comment**

Under the experimental conditions reported the test substance, benzoic acid, 2-[4-(diethylamino)-2-hydroxybenzoyl]-, hexylester, was non-clastogenic in the absence and presence of irradiation in the *in vitro* chromosome aberration assay using the Chinese Hamster V79 cell line.

**3.3.11. Human data**

No data submitted

**3.3.12. Special investigations**

No data submitted

## 3.3.13. Safety evaluation (including calculation of the MoS)

## CALCULATION OF THE MARGIN OF SAFETY

**Diethylamino Hydroxybenzoyl Hexyl Benzoate**  
(UV Filter)

This safety calculation only considers dermal exposure.

*Maximum dermal absorption of test substance reported was 0.15%.*

The SCCNFP calculated a **global daily exposure value** for all cosmetic products that one person may daily apply on the skin. In a worst-case scenario, considering the consumer would use a set of cosmetic products containing the same substance, the SCCNFP-value of **17.79 g/day** will have to be used in the calculation of the MoS [SCCNFP/0321/00]. Additional exposure through sunscreen products should also be considered. For a **sunscreen lotion**, an application of **18.0 g/day** is assumed to be a realistic value. Thus, for the calculation of MoS it is assumed that (17.79 + 18.0 ~ 36) 36 g cosmetics per day containing 10% diethylamino hydroxybenzoyl hexyl benzoate is used.

Total amount of cosmetics used	A g/day	=	36.0 g/day
Concentration of the ingredient under study	C (%)	=	10%
Total exposure of the ingredient under study	T (mg/day)	=	3600 mg/day
Dermal Absorption expressed as a percentage	DA <sub>p</sub> (%)	=	0.15%
Default human body weight		=	60 kg
Systemic Exposure Dosage (SED)	(3600 × 0.015/60)	=	0.09 mg/kg bw/d
No observed adverse effect level (mg/kg) (rat, teratogenicity oral, maternal toxicity)	NOAEL	=	200 mg/kg bw

<b>Margin of Safety</b>	<b>NOAEL / SED</b>	<b>=</b>	<b>2222</b>
-------------------------	--------------------	----------	-------------

## 3.3.14. Discussion

The safety has only been considered for dermal exposure.

If it is intended that it should be widely used, the environmental aspects should be considered (It has been proposed that Uvinul A Plus should be labelled R53: May cause long-term adverse effects in the aquatic environment [draft 31<sup>st</sup> adaptation to technical progress of directive 67/584/EEC on dangerous substances]).

Diethylamino hydroxybenzoyl hexyl benzoate has low acute oral toxicity; more than 2000 mg/kg bw in the rat. A NOEL, derived from an oral 90-day study in rats was about 250 mg/kg bw/day. In a prenatal development toxicity study, the NOAEL for maternal toxicity was 200 mg/kg bw/day and 1000 mg/kg bw for prenatal developmental toxicity.

Diethylamino hydroxybenzoyl hexyl benzoate is not irritating to the skin of guinea pigs for treatments up to 14 days. It caused transient irritation to the rabbit eye. A study of skin sensitisation in guinea pigs cannot be evaluated.

The percutaneous absorption was  $0.10 \pm 0.12 \mu\text{g}/\text{cm}^2$  or  $0.04 \pm 0.05\%$  (Maximum value:  $0.31 \mu\text{g}/\text{cm}^2$  or  $0.15\%$ ).

---

Diethylamino hydroxybenzoyl hexyl benzoate did not induce mutations in a bacteria test or in a mammalian gene test or chromosome aberration in V79 cells in the dark or under irradiation with artificial sunlight. It is neither phototoxic nor photosensitising.

No data on possible carcinogenic effect has been presented.

#### 4. CONCLUSION

Based on the information provided, the SCCP is of the opinion that the use of diethylamino hydroxybenzoyl hexyl benzoate at a maximum concentration of 10% w/w in cosmetic products, including sunscreen products does not pose a risk to the health of the consumer.

Only the dermal application of diethylamino hydroxybenzoyl hexyl benzoate was considered. Due to lack of data with regard to inhalation exposure and toxicity, the safety of applications which would result in consumer exposure via the inhalation route could not be assessed.

#### 5. MINORITY OPINION

Not applicable

#### 6. REFERENCES

1. Gamer A.O., Hoffman H.D., 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoesaure hexylester-Acute oral toxicity study in Wistar rats. Project n° 10A0408/991123 BASF AG Product Safety Regulations, Toxicology and Ecology. D 67056 Ludwigshafen. (2000)
2. Wiemann C., Hellwig J. 2-(4-Diethyl amino-2-hydroxybenzoyl)-benzoesaure-hexylester -Acute dermal irritation / corrosion in rabbits. Project n° 18H0408/992237 BASF AG Product Safety Regulations, Toxicology and Ecology D-67056 Ludwigshafen (2000)
3. Wiemann C., Hellwig J. 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoesaure-hexylester - Acute eye irritation in rabbits. Project n° 11H0408/992236 BASF AG Product Safety Regulations, Toxicology and Ecology D-67056 Ludwigshafen (2000)
4. Engelhardt G., Hoffman H.D. Salmonella Typhimurium/ Escherichia Coli Reverse Mutation Assay (Standard Plate Test and Preincubation Test) with 2-(4-Diethylamino-2-hydroxybenzoyl)benzoesaure-hexylester. Project n° 40M0408/994145 BASF AG Product Safety Regulations, Toxicology and Ecology D-67056 Ludwigshafen (2000)
5. Engelhardt G., Hoffman H.D. In vitro Chromosome Aberration Assay with 2-(4-Diethylamino-2-hydroxybenzoyl)benzoesaure-hexylester in V 79 Cells. Project n° 32M0408/994163 BASF AG Product Safety Regulations, Toxicology and Ecology. D-67056 Ludwigshafen (2000)
6. Engelhardt G., Czich A., Volkner W., Hermann F. Chromosome Aberration Test in vitro: Photomutagenicity in Chinese Hamster V79 Cells with 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoesaure-hexylester. Project n° 34M0408/999045 RCC Cytotest Cell Research GmbH D-64380 Rossdorf on behalf of BASF AG (2000)
7. Engelhardt G., Sokolowski A., Volkner W., Hermann F. Photomutagenicity in a Salmonella Typhimurium and Escherichia Coli Reverse Mutation Assay with 2-(4-Diethyl



- 
- amino-2-hydroxybenzoyl)-benzoic acid hexyl ester. Project n° 41M0408/999046 RCC Cytotest Cell Research GmbH D-64380 Rossdorf on behalf of BASF AG (2000)
8. Marciaux X., Guillaumat P.O., Phototoxic and photoallergenic potential by cutaneous route in guinea pigs. Project number 48H0408/999054 Centre International de Toxicologie (CIT) BP 563 F-27005 Evreux on behalf of BASF AG (2001)
  9. Wiemann D., Glos M., Volkner W., Hermann F. Cytotoxicity Assay in vitro with Balb/C3T3 Cells: Neutral Red (NR) Assay with 2-(4-Diethyl amino-2-hydroxybenzoyl)-benzoic acid hexylester at simultaneous Irradiation with Artificial Sunlight. Project n° 99H0408/999058 RCC Cytotest Cell Research GmbH D-64380 Rossdorf on behalf of BASF (2001)
  10. Wiemann C., Hellwig J. 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoic acid hexylester - Maximization Test in guinea pigs. Report n° 30H0408/992238 BASF AG Product Safety Regulations, Toxicology and Ecology D-67056 Ludwigshafen (2000)
  11. Mellert W., Deckardt K., Gembardt C., van Ravenzwaay B. 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoic acid hexylester- Subchronic toxicity study in Wistar rats, Administration in the diet for 3 months. Project n° 50S0408/99093. BASF AG Product Safety Regulations, Toxicology and Ecology D-67056 Ludwigshafen (2001)
  12. Schilling K., Hellwig J., van Ravenzwaay B. 2-(4-Diethylamino-2-hydroxybenzoyl)-benzoic acid hexylester- Prenatal Developmental Toxicity Study in Wistar Rats, Oral Administration (Gavage). Project n° 30R0408/99112. BASF AG Product Safety Regulations, Toxicology and Ecology D-67056 Ludwigshafen (2001)
  13. Wiemann C., Hellwig J., Leibold E. Study on dermal absorption of 2-(4-Diethylamino-2-hydroxybenzoyl)benzoic acid hexylester through pig skin epidermal membranes in vitro, project no. 51 H0408/992300, draft report, Dec. 2001 BASF AG Product Safety Regulations, Toxicology and Ecology. D-67056 Ludwigshafen (2001)
  14. Bock U., Kiefer M., Haltner E. Dermal transport of 2-(4-Diethylamino-2-hydroxybenzoyl)benzoic acid from an emulsion across porcine skin in vitro (STP 017-00) study report STP 017-00, 19.09.2003. Across Barriers GmbH, Saarbrücken, Germany
  15. BASF AG, Department of Product Safety, Uvinul A Plus - Study of skin irritation in Guinea pigs. Open application to the intact skin (14 applications, unpublished results. Project No 99H0636/02074, March 26, 2004
- I. RCC – CCR Study number 1046900. Cell mutation assay at the thymidine kinase locus (tk +/-) in mouse lymphoma L5178Y cells with Uvinul A Plus BASF-Project no.: 52M0636/029033. Final report. Study completion date: December 28, 2006